Drug intelligence / Profile preview

TSA521

Development stage: Preclinical
Lead developer: TheraSource
Modality: Small Molecules

Overview

**TSA521** is a novel **small molecule** drug in preclinical development for the treatment of **sepsis** and associated inflammation. It potently inhibits the release of proinflammatory cytokines and chemokines, which aggravate and perpetuate the inflammatory response in sepsis.[1][3][5][7]

Beyond the preview

Go deeper on TSA521.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSA521.

Explore the full profile